SureNano Science Advances GEP-44 Toward Clinical Trials in Obesity Market

SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) has taken a significant step toward clinical development by initiating an FDA-aligned IND-enabling GLP toxicology and pharmacology program for its lead drug candidate GEP-44. This multi-receptor peptide targets obesity and type 2 diabetes, positioning the company as a nimble player in the booming GLP-1 therapeutic market, which is projected to reach $200 billion in sales by 2030. The studies will assess safety, dosing thresholds, and pharmacological effects across multiple species, with preclinical results showing GEP-44 holds its own against blockbuster drugs like Ozempic, Mounjaro, and Wegovy. Successful outcomes could pave the way for a Phase I clinical trial in Australia, subject to regulatory submission.

Beyond its obesity and diabetes pipeline, SureNano is exploring acquisition or licensing of Ibogaine-related intellectual property for potential mental health and addiction treatments, signaling a broader pharmaceutical focus. The company’s transition toward a pharmaceutical model follows its acquisition of GlucaPharm, now operating in the rapidly expanding GLP market. SureNano’s GEP-44 compound, developed by Syracuse University, is a second-generation incretin-based therapy licensed by the company. With the GLP-1 receptor agonist market expected to see ~25 million patients in the U.S. alone by 2030, SureNano aims to capture a share of this lucrative space. For more details, read the full article at InvestorWire.

SureNano’s efforts are part of a broader trend where smaller biotech firms challenge industry giants in the obesity and diabetes market. The company’s ability to advance GEP-44 through preclinical phases will be critical in determining its competitiveness. As the GLP-1 market expands, driven by high demand for effective weight loss and diabetes management therapies, SureNano’s progress could offer investors a unique opportunity in a high-growth sector. The company’s stock is traded under the ticker SURNF, and updates are available in its newsroom at https://ibn.fm/SURNF.